Latest Trastuzumab Stories

INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2010 of approximately $74 million, as compared with actual results of $58.3 million for the fourth quarter of 2009, a 27 percent year-over-year increase. The growth is primarily driven by increased third quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and Tysabri® for which PDL receives royalties...

Scientists at IRB Barcelona have provided new data on how certain types of aggressive breast cancer bypass tumour suppression mechanisms.About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB...

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.Scientists in the USA have studied 20 genes that are targeted by existing therapies and found that there are significant changes to these genes in a broad range of...

Researchers find erythropoiesis-stimulating drugs cut response to HER2 targeted therapyRed-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell."Our research indicates when the two drugs were used at the same time, Herceptin was less effective," said study...

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly...

DETROIT, Oct. 18 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer - triple-negative breast cancer. The research is exclusive to the Karmanos Cancer Institute. (Logo:...

(Ivanhoe Newswire) -- Patients with triple-negative breast cancer can now receive more personalized treatment. The may have a unique biomarker that would enable them to receive more targeted therapy, a new study says.According to The Breast cancer Foundation, triple-negative cancer is not one disease, but many different forms of cancer all originating in the breast. Because triple-negative cancers are breast cancers that have tested negative for estrogen receptors, these cancers do not...

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.Aggressive breast cancers with poor prognosis typically have abnormal levels of the protein HER2 (the tyrosine kinase human epidermal growth factor receptor 2). The new elastomeric, rubber-like device is designed to efficiently...

INCLINE VILLAGE, Nev., Sept. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase. The growth is primarily driven by increased second quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and Tysabri® for which PDL receives royalties in...

BEIJING, July 15 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its HER-2 FISH probe has been chosen to be used in a research project focusing on cancer targeted therapy standardization, as well as early cancer detection and treatment, which is sponsored by the Chinese Ministry of Health. One of the subjects of this research project is to standardize...